Literature DB >> 19553934

COX-1 and vascular disease.

P M Vanhoutte1.   

Abstract

Since the discovery of the pivotal role of cyclooxygenase (COX) in the metabolism of arachidonic acid, vascular biologists have been confronted with the duality of this system. Indeed, one substrate (arachidonic acid) transformed by one enzyme (COX) yields end products (endoperoxides) that exist only very briefly before being metabolized to more stable prostanoids by a set of specific downstream synthases that were initially believed to be tissue specific. For instance, platelets contain mainly the synthase that produces thromboxane A(2) (a potent proaggregatory and vasoconstrictor substance), whereas endothelial cells contain mainly the enzyme that generates prostacyclin (an equally potent antiaggregatory and vasodilator substance). The overproduction of thromboxane A(2) by platelets leads to thrombosis; endothelial cells resist vascular occlusion by producing prostacyclin. This duality of the metabolism of arachidonic acid has dominated our thinking about atherothrombosis for decades, and rightfully still does. As scientific understanding progressed, it became evident that two isoforms of COX exist: COX-1 and COX-2. COX-1 was initially considered to be the "good," constitutive isoform, whereas COX-2 appeared to be mainly a "bad" inducible enzyme involved in inflammatory responses. However, more recently, the unexpected events resulting from the widespread use of selective COX-2 inhibitors has suggested that, from a cardiovascular point of view, the products of COX-2 exert a protective role and that this isoform cannot necessarily be regarded as "bad." Likewise, evidence has emerged that initiation of the metabolism of arachidonic acid by COX-1 is not necessarily a "good" thing in terms of vascular protection. This brief review focuses on the potential contribution of endothelial COX-1 to vascular dysfunction. It is based on a number of review articles, to which the reader will be referred in order to identify the original references to the statements made; these references are not cited here because of space limitations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553934     DOI: 10.1038/clpt.2009.108

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.

Authors:  Michel Félétou; Ralf Köhler; Paul M Vanhoutte
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  Eicosanoids, β-cell function, and diabetes.

Authors:  Pengcheng Luo; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-03       Impact factor: 3.072

3.  The endothelial saga: the past, the present, the future.

Authors:  Dragomir N Serban; Bernd Nilius; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-03-07       Impact factor: 3.657

Review 4.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

Review 5.  Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.

Authors:  Takayuki Matsumoto; Styliani Goulopoulou; Kumiko Taguchi; Rita C Tostes; Tsuneo Kobayashi
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

6.  Effects of Toll-Like Receptor 4 Antagonists Against Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage in Mice.

Authors:  Fumihiro Kawakita; Masashi Fujimoto; Lei Liu; Fumi Nakano; Yoshinari Nakatsuka; Hidenori Suzuki
Journal:  Mol Neurobiol       Date:  2016-10-13       Impact factor: 5.590

7.  Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.

Authors:  Md Jashim Uddin; Anna V Elleman; Kebreab Ghebreselasie; Cristina K Daniel; Brenda C Crews; Kellie D Nance; Tamanna Huda; Lawrence J Marnett
Journal:  ACS Med Chem Lett       Date:  2014-10-12       Impact factor: 4.345

Review 8.  Regulation of the human coronary microcirculation.

Authors:  Andreas M Beyer; David D Gutterman
Journal:  J Mol Cell Cardiol       Date:  2011-10-12       Impact factor: 5.000

9.  Circulating blood endothelial nitric oxide synthase contributes to the regulation of systemic blood pressure and nitrite homeostasis.

Authors:  Katherine C Wood; Miriam M Cortese-Krott; Jason C Kovacic; Audrey Noguchi; Virginia B Liu; Xunde Wang; Nalini Raghavachari; Manfred Boehm; Gregory J Kato; Malte Kelm; Mark T Gladwin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

Review 10.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.